Clinical Trial Update: Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy

View source ↗

Summary

This completed clinical trial evaluated anti-E1E2 epitope-binding antibodies in combination with HCV triple therapy for hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies)

Snippet

Sponsor: Hospices Civils de Lyon | Conditions: Hepatitis C | Status: COMPLETED